Regeneron Pharmaceuticals Inc. v Kymab Ltd
| Jurisdiction | England & Wales |
| Neutral Citation | [2020] UKSC 27 |
| Year | 2020 |
| Court | Supreme Court |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
7 cases
-
Merck Sharp and Dohme Corporation v Wyeth LLC (No 3)
...Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157 Regeneron Pharmaceuticals Inc (Respondent) v Kymab Ltd (Applicant) [2020] UKSC 27; Bus LR 1394 Regeneron Pharmaceuticals, Inc v Kymab Ltd [2018] EWCA Civ 671; RPC 14 Schering Biotech Corp’s Application [1993] RPC 249 Zipher Ltd v......
-
ToolGen Incorporated v Fisher (No 2)
...AB (2013) 101 IPR 11 RD Werner & Co Inc v Bailey Aluminium Products Pty Ltd (1989) 25 FCR 565 Regeneron Pharmaceuticals Inc v Kymab Ltd [2020] UKSC 27 Schering Biotech Corp’s Application [1993] RPC 249 Schlumberger Holdings Ltd v Electromagnetic Geoservices AS [2010] RPC 33 Valensi v Britis......
-
Saint-Gobain Adfors S.A.S. (a company existing under the laws of France) v 3M Innovative Properties Company (a company existing under the laws of Delaware, United States)
...to be performed without undue burden across the whole scope of the claim, I was referred to the judgment of Lord Briggs in Regeneron Pharmaceuticals Inc v Kymab Ltd [2020] UKSC 27 and to Birss LJ's analysis in Illumina Cambridge Ltd v Latvia MGI Tech SIA [2021] EWHC 57 (Pat) at 196 In its......
-
Illumina Cambridge Ltd v Latvia MGI Tech Sia
...that, if they are not obvious, they are insufficient, in part having regard to the recent Supreme Court decision in Regeneron v Kymab [2020] UKSC 27. 11 In terms of infringement, MGI has various systems alleged to infringe. One system is called StandardMPS and the other is called CoolMPS. B......
Request a trial to view additional results
1 firm's commentaries
-
Case Analysis: Sandoz And Teva v Bristol Myers Squibb ' Court Of Appeal
...is not the first time that a pharma company has been shown to have jumped the gun, or gone too broad in their claims: Regeneron v Kymab [2020] UKSC 27 is a case in point. Nevertheless, the cost benefit analysis, taking such risks into account, most likely still points to early filing: the o......
1 books & journal articles
-
THE DEATH OF THE GENUS CLAIM.
...& III.B.2.b. (436.) This new full-scope doctrine has been exported to United Kingdom law. See Regeneron Pharms. Inc. v. Kymab Ltd. [2020] UKSC 27 [56] (holding that "[e]nablement across the scope of a product claim is not established merely by showing that all products within the releva......